Ro-42-5892 is the first orally active renin inhibitor Newsletter Article 17 February 2013 Pages: 1 - 1
Swings and roundabouts abound in the choice of the optimum antihypertensive Newsletter Article 17 February 2013 Pages: 3 - 3
Upjohn admits omitting ‘Halcion’ adverse effect reports Newsletter Article 17 February 2013 Pages: 4 - 4
Multidimensional pharmacoeconomic analysis of respiratory medicine awaited Newsletter Article 17 February 2013 Pages: 6 - 6
The protective effects of SmithKline Beecham’s novel anticonvulsants Newsletter Article 17 February 2013 Pages: 6 - 6
Isolated liver perfusion enables complete remissions with mitomycin Newsletter Article 17 February 2013 Pages: 6 - 7
Janssen’s sabeluzole - an effective “memory enhancer” Newsletter Article 17 February 2013 Pages: 7 - 7
A clear difference between enalapril and perindopril in the elderly Newsletter Article 17 February 2013 Pages: 9 - 9
Beta blockers get the nod in intermittent claudication Newsletter Article 17 February 2013 Pages: 10 - 10
First controlled study of ‘SLOW MAG’ for continued tocolysis Newsletter Article 17 February 2013 Pages: 10 - 11
…and salmeterol is more potent and longer acting than salbutamol Newsletter Article 17 February 2013 Pages: 11 - 11
Patient compliance in hypertension depends on good education Newsletter Article 17 February 2013 Pages: 11 - 11
Captopril improves myocardial segment lengths after acute MI Newsletter Article 17 February 2013 Pages: 12 - 13
Early intervention with metoprolol after acute MI - long term prognosis Newsletter Article 17 February 2013 Pages: 13 - 13
Patients lack nonpharmacological advice on BP reduction Newsletter Article 17 February 2013 Pages: 13 - 13
Verapamil enhancement of photodynamic tumour destruction - conflicting evidence Newsletter Article 17 February 2013 Pages: 15 - 15
Get in early to combat chronic pseudomonas infection in cystic fibrosis Newsletter Article 17 February 2013 Pages: 15 - 15
Meta-analysis confirms iloprost efficacy in severe peripheral ischaemia Newsletter Article 17 February 2013 Pages: 15 - 16
Twice-daily oral ondansetron is as good as thrice-daily … Newsletter Article 17 February 2013 Pages: 16 - 16
…and ondansetron is safe and effective in children Newsletter Article 17 February 2013 Pages: 16 - 16
Patients prefer tetracosactide to methylprednisolone in emesis Newsletter Article 17 February 2013 Pages: 16 - 16
Synthelabo investigates new once-daily SR diltiazem Newsletter Article 17 February 2013 Pages: 16 - 16
Antibacterial prophylaxis reduces RTIs in mechanically ventilated patients Newsletter Article 17 February 2013 Pages: 18 - 18
…and a multicentre study of lisinopril vs atenolol is reported Newsletter Article 17 February 2013 Pages: 19 - 19